Laekna Inc. Announces Presentation of Clinical and Preclinical Study Results for LAE02, LAE03, and LAE123 at 2025 ADA
Laekna, Inc., a company incorporated in the Cayman Islands, has announced the presentation of clinical and preclinical study results for its drug candidates, LAE02, LAE03, and LAE123, at the 85th scientific sessions of the American Diabetes Association $(ADA.AU)$ held in 2025. The studies focused on the potential use of these drugs for muscle growth and fat reduction. The results included data from the phase I SAD study of LAE102, an ActRIIA-selective antibody, for treating obesity. This study involved both intravenous and subcutaneous cohorts and concluded that LAE102 was well tolerated, with no serious adverse events reported. The presentations took place on June 22, 2025, at the McCormick Place Convention Center in Chicago, Illinois, USA. Shareholders and potential investors are advised to exercise caution, as these drug candidates may not ultimately be successfully developed and commercialized.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief on June 23, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.